Veterinary Medicine · AllergySafety Signalregulatorymid-term

FDA Reports Increase in Accidental Overdoses of Apoquel Chewable in Dogs

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/3/2026, 6:33:21 AM

Assessment confidence: 53% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The rise in accidental overdoses of Apoquel Chewable raises significant safety concerns that could affect its market position and regulatory scrutiny. Pharma strategy teams must be vigilant in monitoring FDA guidance and assessing the implications for product safety and competitive dynamics. Regulatory context from FDA (Preventing Accidental Apoquel Chewable Overdoses) supports the near-term read. Assessment grounded in 24 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the safety profile of Apoquel and consider strategies to mitigate overdose risks. The strongest clinical anchor is A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (ClinicalTrials.gov), sponsor/company relevance (roche). In Veterinary Medicine · Allergy, 8 regulatory and 6 competitive items passed relevance filtering for Apoquel.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease (Merck) — sponsor/company relevance (merck). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need.

Regulatory Outlook

Regulatory risk is concentrated around Preventing Accidental Apoquel Chewable Overdoses (FDA). Entity match (apoquel). Relevant agencies in corpus: FDA, MHRA. The FDA's increased attention on safety signals could lead to changes in prescribing information or additional regulatory requirements for Apoquel.

Key Risks

Elevated medium regulatory exposure for Apoquel could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Increased safety concerns may lead to reduced usage of Apoquel, impacting revenue and market share, while potentially benefiting alternative treatments.
This guidance sets out the warning statements which should appear on the label and/or in the leaflet of certain medicines.
How to package medicines for sale and what information you must provide to consumers and healthcare professionals.
Upside for Apoquel may improve if A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for El (ClinicalTrials.gov) delivers favorable follow-through.
Diabetes · Insulin Delivery · Safety Signal · This recall could impact Insulet's market share and patient trust, potentially benefiting competitors in the insulin delivery space.

What Would Change This Assessment

This becomes more urgent if Monitor for further FDA guidance or changes in prescribing information related to Apoquel.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Preventing Accidental Apoquel Chewable Overdoses
FDAhigh relevance
Entity match (apoquel)
FDA document
View source
Guidance: Warning statements for labels and leaflets of certain medicines
MHRAmedium relevance
Regulatory pathway relevance (label)
FDA document
View source
Medicines: packaging, labelling and patient information leaflets
MHRAmedium relevance
Regulatory pathway relevance (label)
FDA document
View source
Lower dose needle-free allergy treatment approved for younger children
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Borderline products: how to tell if your product is a medicine
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Guidance: Medicines that you cannot export from the UK or hoard
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
A Clinical Study on the Safety and Efficacy of Wide-Band Ultrasound Combined With Traditional Chinese Medicine Preparations in the Prevention and Treatment of Keloids
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and Safety of Fluticasone Propionate Nebulized Suspension for Wheezing Diseases in Infants Aged 0-24 Months
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for El
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Abiomed Recalls Impella CP Sets Due to Low Purge Pressure Risk
Humanexa Signalsmedium relevance
Moderate corpus alignment
Insulet Recalls Omnipod Pods Due to Insulin Leakage Risk
Humanexa Signalsmedium relevance
Moderate corpus alignment
Hologic Recalls BioZorb Markers Due to Patient Complications Risk
Humanexa Signalsmedium relevance
Moderate corpus alignment
Abiomed Issues Update on Automated Impella Controllers Due to Software Error
Humanexa Signalsmedium relevance
Moderate corpus alignment

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Apoquel
Zoetis

Commercial impact

medium

Increased safety concerns may lead to reduced usage of Apoquel, impacting revenue and market share, while potentially benefiting alternative treatments.

Regulatory impact

medium

The FDA's increased attention on safety signals could lead to changes in prescribing information or additional regulatory requirements for Apoquel.

What to watch

Monitor for further FDA guidance or changes in prescribing information related to Apoquel.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.